clients such as Pfizer's and their subsidiaries in China. This is expected to translate to further demand for JCM's macrolide API business in both the domestic and international markets. http://pharmabiz.com/NewsDetails.aspx?aid=86815&sid=2
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.